Skip to main content
Signal8

EOM Pharmaceutical Holdings Reports FDA Clearance of an IND for a Clinical Trial in Cachectic Cancer Patients

$IMUCPress releaseMay 27, 2026, 8:30 AM ET

EOM Pharmaceutical Holdings received FDA clearance for its IND application to conduct a Phase 2a clinical trial of EOM613 in cachectic cancer patients. The open-label study will enroll approximately 20 Stage 4 cancer patients with Karnofsky Performance Scores of 40-80% and assess weight, lean body mass, and quality of life over three months.

Key figures

Drug Name
EOM613
Phase Of Trial
Phase 2a
Age range
18-80
Enrollment target
20
Start date estimate
Q3 2026
Karnofsky score range
40-80%
Trial duration months
3
Min life expectancy months
4

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.